维生素 C 给药对骨髓瘤或淋巴瘤自体干细胞移植中中性粒细胞恢复无影响：一项盲法、随机、安慰剂对照试验

Vitamin C is an important micronutrient for various immune cells. It increases phagocytic cell function and is necessary for T and natural killer (NK) cell development. Patients in need of an autologous hematopoietic stem cell transplantation (HSCT) are often vitamin C-depleted.

We therefore hypothesized that vitamin C supplementation could improve immune recovery in autologous HSCT patients. This blinded, placebo-controlled trial included 44 patients randomized to receive vitamin C or a placebo. The following outcome measures used were clinical and immunological parameters, among others: time to neutrophil recovery, serum, and intracellular vitamin C values.

Twenty-one patients received vitamin C, and 23 received a placebo. The time to neutrophil recovery did not differ between the two groups at 11. 2 days ( p = 0. 96). There were no differences in hospitalization time (19. 7 vs. 19. 1 days, p = 0. 80), the incidence of neutropenic fever (57% vs. 78%, p = 0. 20), or 3-month overall survival (90. 5% vs. 100%, p = 0. 13). Bacteremia seemed to occur less in the vitamin C group (10% vs. 35%, p = 0. 07).

Our study shows no benefit from vitamin C supplementation on neutrophil recovery and hospitalization, despite possible lower rates of bacteremia in the vitamin C group.

Therefore, we do not advise vitamin C supplementation in this treatment group.